Form 8-K - Current report:
SEC Accession No. 0001193125-25-133773
Filing Date
2025-06-03
Accepted
2025-06-03 07:38:05
Documents
19
Period of Report
2025-06-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d88500d8k.htm   iXBRL 8-K 53137
2 EX-1.1 d88500dex11.htm EX-1.1 176566
3 EX-4.1 d88500dex41.htm EX-4.1 77482
4 EX-4.2 d88500dex42.htm EX-4.2 100982
5 EX-5.1 d88500dex51.htm EX-5.1 13198
6 EX-99.1 d88500dex991.htm EX-99.1 11362
10 GRAPHIC g88500snap2.jpg GRAPHIC 4690
11 GRAPHIC g88500snap3.jpg GRAPHIC 13554
  Complete submission text file 0001193125-25-133773.txt   693670

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA xlo-20250602.xsd EX-101.SCH 2835
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE xlo-20250602_lab.xml EX-101.LAB 18737
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xlo-20250602_pre.xml EX-101.PRE 11698
21 EXTRACTED XBRL INSTANCE DOCUMENT d88500d8k_htm.xml XML 3765
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 251017170
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)